Bayer-Algeta's prostate cancer drug Xofigo wins FDA nod

05/16/2013 | Bloomberg · American City Business Journals

The FDA approved Bayer and Algeta's Xofigo injection, or radium-223 dichloride, to treat patients with castration-resistant prostate cancer, three months earlier than expected. Bayer also submitted an application in Europe and hopes to win approval in coming months.

View Full Article in:

Bloomberg · American City Business Journals

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Assistant General Counsel
Cardinal Health
Columbus, OH
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC